SCHEMBL338686

SCHEMBL338686

O=C(O)CCP(=O)(O)CCO

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 1/20 0.53
GRM6 O15303 1/20 0.53
GRM7 Q14831 1/20 0.53
GRM4 Q14833 1/20 0.53
CAMK2A Q9UQM7 1/20 0.42
GRM3 Q14832 2/20 0.39
GPR84 Q9NQS5 1/20 0.39
FFAR1 O14842 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
LMNA P02545 2/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
FOLH1 Q04609 2/20 0.38
FFAR3 O14843 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2403116 0.89 GRM8 (0.61) GRM8GRM6GRM7GRM4GRM3
SCHEMBL9061995 0.87 GRM8 (0.59) GRM8GRM6GRM7GRM4GRM3
SCHEMBL2832674 0.81
SCHEMBL12145014 0.78 LMNA (0.52) GRM8GRM6GRM7GRM4GPR84
SCHEMBL340145 0.78 FFAR3 (0.55) GRM8GRM6GRM7GRM4GPR84
SCHEMBL8844627 0.76 FFAR3 (0.50) GRM8GRM6GRM7GRM4GRM3
SCHEMBL338870 0.75 FFAR3 (0.50) GRM8GRM6GRM7GRM4GRM3
SCHEMBL339162 0.75 GABBR2 (0.57) GRM8GRM6GRM7GRM4GPR84
SCHEMBL2378568 0.73 FFAR3 (0.48) GRM8GRM6GRM7GRM4GRM3
SCHEMBL3954142 0.73 FFAR3 (0.48) GRM8GRM6GRM7GRM4GRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097753-B2 Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation CLARIANT FINANCE (BVI) LIMITED (VG) 2012-01-17 US disclosed
EP-1832594-B1 Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application CLARIANT FINANCE BVI LTD (VG) 2011-05-18 EP disclosed
US-20070213436-A1 Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation CLARIANT INTERNATIONAL LTD 2007-09-13 US disclosed
EP-1832594-A1 Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application CLARIANT INTERNATIONAL LTD. (CH) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213436-A1 Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation PAH, ALKBH3, FTO GRM8 3467/4885GRM6 1547/4885GRM7 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.